周剂量紫杉醇联合顺铂作为乳腺癌术后辅助化疗方案的临床观察

A Clinical Study of Weekly Paclitaxel Combined with Cisplatin as Postoperative Adjuvant Chemotherapy Regimen in Breast Cancer

目的评价周剂量紫杉醇联合顺铂方案(wTP方案)作为乳腺癌术后辅助化疗方案的远期疗效和安全性。方法 20例乳腺癌术后患者均给予wTP方案化疗,21～28 d为1个周期,共4～6个周期。给药后监测毒副反应和生存情况。结果全组20例患者的5年生存率为90%。主要毒副反应为骨髓抑制、胃肠道反应,均为可逆性。结论 wTP方案作为乳腺癌术后辅助化疗方案毒副反应可耐受,患者长期生存率高。

Objective To investigate the safety and long-term survival of weekly paclitaxel combined with cisplatin （wTP） as a postoperative adjuvant chemotherapy regimen in breast cancer. Methods Twenty patients with breast cancer were treated postoperatively with wTP regimen, and repeated every 21-28 days as a cycle, and 4-6 cycles were achieved. The toxicities and survival rate were evaluated after chemotherapy. Results The 5-year survival rate was 90%. The main toxicities were myelosuppression and gastrointestinal reaction, but were all reversible. Conclusion wTP regimen is safe, and the toxicities can be tolerable. The long-term survival rate is high.